Dr. Hatim Karachiwala is a Medical Oncologist and a clinical assistant professor in the Department of Oncology at the University of Calgary. Dr. Karachiwala is an active participant in clinical research, specializing in the area of gastrointestinal oncology. He is currently the clinical trial research lead for the Gastrointestinal oncology group. He has been the primary investigator on many clinical trials and continues to work on more novel approaches to treating patients with incurable cancers.
Karachiwala, Hatim
Medical Oncology
Associate Professor
Web Presence:
Biography
Area of Focus
Gastrointestinal Oncology
Summary of Research
- A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site (Mar 31, 2026)
- Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options (Nov 20, 2025)
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (May 24, 2025)
Area Of Focus
Gastrointestinal Oncology
Summary Of Research
- A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site (Mar 31, 2026)
- Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options (Nov 20, 2025)
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (May 24, 2025)